Ionis Pharmaceuticals, Inc. (IONS) Stock: Price, Forecast & Analyst Target
Ionis Pharmaceuticals, Inc. (IONS) — MoonshotScore 17/100 (Weak band), calculated Nov 18, 2026. Price $27.22 (-0.62%), as of the Nov 19, 2026 trading session; market cap $4.53B.
Educational signal · not a buy or sell recommendation · How to read this
Ionis Pharmaceuticals, Inc. · IONS · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Ionis develops and commercializes RNA-targeted medicines for rare and serious diseases, with named products on the market and a broad clinical pipeline supported by major pharmaceutical collaborations. The equity case depends on whether TRYNGOLZA and DAWNZERA can turn improving revenue into durable operating leverage while research spending remains heavy.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Ionis Pharmaceuticals (IONS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.
- quarterly revenue $157M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 3 reports
- Altman Z 0.20 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 18 | Weak | |
| 18 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 17 | Weak | |
| 17 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $27.22 | |
| Change on the day | -0.62% | |
| 52-week range | $26.88–$86.74 | |
| Market capitalisation | $4.53B | — |
| Shares traded on the day | 3.06M | |
| Beta (volatility vs the S&P 500) | 0.4 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Ionis Pharmaceuticals (IONS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ionis Pharmaceuticals (IONS), and what does it report?
Short answer · as of
Ionis is not merely a drug developer awaiting a clinical verdict. It sells RNA-targeted medicines such as TRYNGOLZA and DAWNZERA, while therapies including WAINUA, SPINRAZA and QALSODY connect its platform to a wider commercial portfolio.
Research dated 2026-09-13.
Reported revenue therefore reflects a hybrid commercial-stage biotechnology business rather than demand for an isolated flagship medicine. Gross profit sits close to revenue, yet research and administrative expense still push operations into loss, so the income statement measures a transition from platform investment toward a broader marketed portfolio.
What do the latest results show for Ionis Pharmaceuticals (IONS)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $157M.
Research dated 2026-09-13.
Revenue has risen across the latest reported periods after a much weaker run. The operating loss narrowed again in the latest period, although the net loss deepened.
Gross profit rose with revenue while research and administrative expense changed less, allowing incremental revenue to carry through to a smaller operating loss. The business remains unprofitable, however, and the annual record shows that higher revenue has not yet produced durable earnings.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $157M | -$129M | -$0.80 (diluted) |
| Q4 FY2025 | $203M | -$229M | -$1.42 (diluted) |
| Q1 FY2026 | $246M | -$93M | -$0.56 (diluted) |
| Q2 FY2026 | $268M | -$115M | -$0.69 (diluted) |
What are the financial strengths and risks for Ionis Pharmaceuticals (IONS)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Liquidity is substantial relative to the observed rate of cash use, and cash and short-term investments recovered from the preceding period while remaining below earlier levels. The wider reporting window still shows an overall cash decline, and operating cash flow has swung sharply between use and generation, making any isolated period a poor guide to self-funding capacity.
Debt exceeds cash and short-term investments, leaving Ionis in net debt despite ample current liquidity. Persistent losses, negative returns, weak quality and distress screens, and demanding sales and book valuations mean slow product uptake or pipeline setbacks could leave the balance sheet carrying continued research spending.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.20 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Ionis Pharmaceuticals (IONS)?
Short answer · as of
Current published price targets run low $53.00 · high $115.00 · consensus $78.13 · median $82.50 against a quoted price of $27.22 (as of Nov 19, 2026).
Research dated 2026-09-13.
Watch whether sequential revenue growth continues and whether gross profit again rises faster than the combined research and administrative burden. That pairing would narrow operating losses for a repeatable reason; revenue growth without expense absorption would not.
Cash conversion needs equal attention. The latest positive operating cash flow followed a severe outflow, so sustained generation alongside a stable cash balance would carry more weight than another isolated inflow.
Commercial uptake for TRYNGOLZA and DAWNZERA, progress in late-stage lipid and rare-neurology programs, and the durability of medicines developed through collaborations are the company-specific observations that can reshape the revenue profile.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Ionis Pharmaceuticals compare with its peers?
Short answer
Ionis Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Unlike biotechnology businesses supported mainly by experimental pipelines, Ionis combines marketed medicines, internal late-stage programs and collaborations with Biogen, GSK, AstraZeneca, Novartis, Roche and Metagenomi.
Its differentiation is an RNA-targeting platform applied across lipid, neurologic, cardiovascular, liver and complement-related diseases. That breadth spreads clinical exposure across distinct disease mechanisms, but the financial profile remains research-intensive: exceptionally high gross margins coexist with large operating losses and volatile cash flow.
| Company | Price | Market value | Score |
|---|---|---|---|
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $41.17 Nov 19, 2026 | $4.51B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $46.41 Nov 19, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $286.94 Nov 19, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| $26.20 Nov 19, 2026 | $3.37B | 66 5-pillar Nov 18, 2026 | |
| $151.02 Nov 19, 2026 | $6.13B | 64 5-pillar Nov 18, 2026 | |
| $21.89 Nov 18, 2026 | $3.71B | 62 5-pillar Nov 18, 2026 | |
| $199.33 Nov 19, 2026 | $80.7B | 31 5-pillar Nov 18, 2026 | |
| Ionis Pharmaceuticals (IONS) — this page | $27.22 | $4.53B | 17 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $53.00 – $115.00
- Consensus target
- $78.13
- Median target
- $82.50
Consensus record · Captured .
Measured against a quoted price of $27.22 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 60
- Identified insiders
- 18
- Purchases
- 3
- Sales
- 14
- Other transactions
- 43
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IONS in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 0.24% | $41.22M | Added +206.9% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ionis Pharmaceuticals (IONS)?
Ionis Pharmaceuticals Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do TRYNGOLZA and DAWNZERA change the Ionis business model?
They add named commercial medicines to a business long defined by RNA-targeted research and pharmaceutical collaborations. Their uptake can make revenue more closely connected to product demand, while the current expense base shows that commercialization has not yet displaced heavy platform investment.
What would olezarsen add beyond TRYNGOLZA?
Olezarsen is being developed for severe hypertriglyceridemia and cardiovascular disease, while TRYNGOLZA addresses familial chylomicronemia syndrome and acute pancreatitis. Its development therefore reaches a different lipid-disease setting within the same RNA-targeted franchise.
Why can Ionis report high gross profit and still lose money?
Research and administrative spending exceed the gross profit generated by current revenue. The latest periods show improving operating leverage, but the annual record still reflects sustained net losses.
Can Ionis fund its RNA-targeted pipeline from current liquidity?
Current liquidity is large relative to observed cash use, but debt exceeds cash and investments and operating cash flow is volatile. Expense discipline and sustained commercial cash generation therefore matter more than the headline liquidity balance alone.
What is the IONS stock price today?
The last price recorded for Ionis Pharmaceuticals, Inc. (IONS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IONS price target?
The analyst consensus price target for Ionis Pharmaceuticals, Inc. (IONS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com